Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program | Zendy

Lynn-Yao Lin | Zendy; Dmitri Debabov | Zendy; William Chang | Zendy; Gregory G. Stone | Zendy; Todd Riccobene | Zendy

Open Access

Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program

Author(s) -

Lynn-Yao Lin,

Dmitri Debabov,

William Chang,

Gregory G. Stone,

Todd Riccobene

Publication year - 2022

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01985-21

Subject(s) - ceftazidime/avibactam , meropenem , pseudomonas aeruginosa , microbiology and biotechnology , klebsiella pneumoniae , broth microdilution , ceftazidime , antimicrobial , biology , avibactam , minimum inhibitory concentration , antibiotic resistance , antibiotics , bacteria , escherichia coli , biochemistry , genetics , gene

In vitro activities of ceftazidime-avibactam (CAZ-AVI) and key comparators against AmpC-overproducingEnterobacterales andP. aeruginosa isolates from four Phase 3 clinical trials and against OXA-48-producingEnterobacterales with multiple resistance mechanisms from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, were evaluated. Susceptibility to CAZ-AVI and comparators was determined by reference broth microdilution methods.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research